Qiagen (QGEN) Set to Post Earnings on Wednesday

Qiagen (NYSE:QGEN) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of $0.6270 per share and revenue of $538.61 million for the quarter. Qiagen has set its FY 2026 guidance at 2.430- EPS. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the company earned $0.60 earnings per share. On average, analysts expect Qiagen to post $2.44 EPS for the current fiscal year and $2.61 EPS for the next fiscal year.

Qiagen Stock Down 0.3%

Shares of QGEN stock opened at $50.20 on Wednesday. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The stock’s 50-day moving average is $44.73 and its two-hundred day moving average is $42.70.

Wall Street Analyst Weigh In

Several research firms recently issued reports on QGEN. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Qiagen in a research report on Thursday, August 6th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $52.00 target price (down from $55.00) on shares of Qiagen in a report on Thursday, October 22nd. DZ Bank downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Finally, TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $45.01.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.